Gen-Probe gets rights to Qualigen's platform:
This article was originally published in Clinica
In what may accelerate its entry into the clinical point-of-care (POC) testing market, nucleic acid test (NAT) maker Gen-Probe has gained exclusive rights to the immunoassay technology behind Qualigen's blood testing system, FastPack. Gen-Probe hopes access to the technology will help it develop a POC NAT system that can identify harmful micro-organisms and genetic mutations, for use in doctors' offices, outpatient clinics and blood screening centres. The San Diego, California firm will pay Qualigen an initial $1m for an 18-month option to license on an exclusive basis.
You may also be interested in...
Royal Philips will make 43,000 medical ventilators by year-end for use in the US and make 2,500 more for the Strategic National Stockpile in a deal with the US government worth $646.7m. See what Philips’ CEO Frans van Houten said about it here.
Pharma manufacturing is operating well below normal levels in India, disrupted by labor absenteeism and supply chain issues amid the ongoing lock-down in the country, though the government is actively engaged in addressing bottlenecks. A speedy recovery is vital not just for domestic supplies.
Moderna is pursuing a single-antigen strategy even though some of its mRNA vaccines have included multiple antigens; the SARS-CoV-2 spike protein likely provides the best antigen for developing immunity against the virus.